ReviewFrontiers in immunology2025
Mechanism of cell death and its application in the repair of inflammatory bowel disease by mesenchymal stem cells.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Apoptosis-driven chromosomal rearrangements in cancer: CAD cleavage, nuclear architecture, and microhomology-mediated end joining.Oncogenesis · 2026Review
- ATG5 overexpression enhances the therapeutic efficacy of mesenchymal stem cells in a mouse colitis model by augmenting anti-inflammatory and antioxidative mechanisms.Stem cell research & therapy · 2026Article
- Dimercaprol Reprograms Intestinal Redox Homeostasis and Organelle Crosstalk to Combat Iron-Induced Gut Dysbiosis Through NRF2/HO-1 Signaling.Antioxidants (Basel, Switzerland) · 2026Article
- Tissue regeneration strategies based on mesenchymal stem cell-derived extracellular vesicles: from bench to bedside.Burns & trauma · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The onset and progression of inflammatory bowel disease (IBD), which encompasses ulcerative colitis and Crohn's disease, are influenced by the immune system, environmental factors, genetics, and intestinal flora. Cell death is a biological phenomenon that occurs in all living organisms; nevertheless, excessive cell death has been linked to IBD, including increased immune and intestinal epithelial cell death and intestinal barrier abnormalities. Anti-tumor necrosis factor medication, which has made significant progress in treating IBD cell death, may fail in some individuals or lose effectiveness over time, necessitating the search for a safe and effective treatment. One of the novel and emerging areas in regenerative and nanomedicine used to regulate cell death is mesenchymal stem cells (MSCs) and their mediators (extracellular vesicles). MSCs and their mediators have been found to attenuate cell death in several illnesses, including IBD. This review explores cell death mechanisms and their implications in IBD, focusing on the potential ameliorative effects of MSCs and their mediators on cell death.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.